Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Other Operating Expenses (2018 - 2025)

Akebia Therapeutics (AKBA) has disclosed Other Operating Expenses for 8 consecutive years, with $53.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Operating Expenses changed N/A to $53.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $162.2 million, a 128.71% increase, with the full-year FY2023 number at -$500000.0, changed N/A from a year prior.
  • Other Operating Expenses was $53.3 million for Q4 2025 at Akebia Therapeutics, up from $44.6 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $53.3 million in Q4 2025 to a low of -$33.3 million in Q3 2021.
  • A 5-year average of $17.7 million and a median of $26.1 million in 2025 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: crashed 4796.34% in 2021, then skyrocketed 20791.76% in 2024.
  • Akebia Therapeutics' Other Operating Expenses stood at $1.0 million in 2021, then grew by 5.34% to $1.1 million in 2022, then crashed by 97.79% to $24000.0 in 2023, then skyrocketed by 147437.5% to $35.4 million in 2024, then surged by 50.58% to $53.3 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Other Operating Expenses are $53.3 million (Q4 2025), $44.6 million (Q3 2025), and $38.1 million (Q2 2025).